Rein Therapeutics Inc.
RNTX - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$22.06M
Close$
$0.13
82.6% downside
Current Fair Value
82.6% downsideOvervalued by 82.6% based on the discounted cash flow analysis.
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $22.06 Million |
|---|---|
| Enterprise Value | $13.51 Million |
| Earnings per Share | $-1.96 |
| Beta | 1.36 |
| Outstanding Shares | 30,354,647 |
Return
| Return on Equity | -90.14% |
|---|---|
| Return on Assets | -75.43% |
| Return on Invested Capital | -87.90% |
Valuation & Multiples
| P/E Ratio | -0.43 |
|---|---|
| PEG | 6.62 |
| Price to Sales | - |
| Price to Book Ratio | 0.73 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -0.27 |
| Enterprise Value to Net Income | -1 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
Last Earnings Call
Report Date
August 14, 2026
EPS Estimate
$-0.17
Consensus analyst estimateRevenue Estimate
-
Consensus analyst estimateNext Earnings Call
Expected Date
November 13, 2026
EPS Estimate
$-0.10
Consensus analyst estimateRevenue Estimate
-
Consensus analyst estimateInstitutional Put/Call Ratio
Compares institutional put options with call options. At 0.00, the ratio is below 1, so institutions hold more calls than puts.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 1.24%▼ 133.31% |
|---|---|
| Total Invested | $301,884▼ 99.29% |
| Investors Holding | 2▼ 57.00% |
About Aileron Therapeutics Inc
10 employees
CEO: James Brian Windsor
Rein Therapeutics Inc. operates as a clinical-stage biopharmaceutical enterprise focused on discovering and bringing to market novel therapeutic solutions for various conditions, notably cancer. The company's leading drug candidate, ALRN...